Arix Bioscience Notes Verona Pharma’s NASDAQ Global Market Listing and $80m Fundraise

28th April 2017

LONDON, 28 April, 2017:

Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Verona Pharma plc, an Arix Bioscience Group Business, that it has raised approximately $80.0 million before expenses in a successful NASDAQ listing.

Verona’s global offering priced of an aggregate of 47,399,001 new ordinary shares, comprising 5,768,000 American Depositary Shares (“ADS”) priced at $13.50 per ADS and 1,255,001 ordinary shares at £1.32 per ordinary share. Gross proceeds were approximately $80.0 million.

“Verona’s successful fundraise and NASDAQ listing further demonstrates the interest in this dynamic company which we believe has the potential to make significant breakthroughs in respiratory medicine. It also provides further validation of the strength of the Arix strategy to invest in and support Group Businesses at the cutting edge of science in areas of unmet medical need.”

Joe Anderson, Chief Executive Officer of Arix Bioscience Plc